Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease

Katrina L. Paumier, Andrew D. Siderowf, Peggy Auinger, David Oakes, Lalitha Madhavan, Alberto J. Espay, Fredy J. Revilla, Timothy J. Collier

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

This study examined whether antidepressants delay the need for dopaminergic therapy or change the degree of motor impairment and disability in a population of early Parkinson's disease (PD) patients. Preclinical studies have indicated that antidepressants modulate signaling pathways involved in cell survival and plasticity, suggesting they may serve to both treat PD-associated depression and slow disease progression. A patient-level meta-analysis included 2064 patients from the treatment and placebo arms of the following trials: FS1, FS-TOO, ELLDOPA, QE2, TEMPO, and PRECEPT. Depression severity was determined at baseline, and antidepressant use was reported in a medication log each visit. Kaplan-Meier curves and time-dependent Cox proportional hazards models determined associations between depression severity and antidepressant use with the primary outcome, time to initiation of dopaminergic therapy. ANCOVAs determined associations with the secondary outcome, degree of motor impairment and disability, reported as annualized change in UPDRS scores from baseline to final visit. When controlling for baseline depression, the initiation of dopaminergic therapy was delayed for subjects taking tricyclic antidepressants compared with those not taking antidepressants. No significant differences were found in UPDRS scores for subjects taking antidepressants compared with those not taking antidepressants. Tricyclic antidepressants are associated with a delay in reaching the end point of need to start dopaminergic therapy. The lack of change in overall UPDRS scores suggests the delay was not attributable to symptomatic effects.

Original languageEnglish (US)
Pages (from-to)880-887
Number of pages8
JournalMovement Disorders
Volume27
Issue number7
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Tricyclic Antidepressive Agents
Antidepressive Agents
Parkinson Disease
Therapeutics
Proportional Hazards Models
Disease Progression
Meta-Analysis
Cell Survival
Placebos
Population

Keywords

  • Antidepressants
  • Depression
  • Disease modifying
  • Parkinson's disease
  • Retrospective study

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Paumier, K. L., Siderowf, A. D., Auinger, P., Oakes, D., Madhavan, L., Espay, A. J., ... Collier, T. J. (2012). Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease. Movement Disorders, 27(7), 880-887. https://doi.org/10.1002/mds.24978

Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease. / Paumier, Katrina L.; Siderowf, Andrew D.; Auinger, Peggy; Oakes, David; Madhavan, Lalitha; Espay, Alberto J.; Revilla, Fredy J.; Collier, Timothy J.

In: Movement Disorders, Vol. 27, No. 7, 2012, p. 880-887.

Research output: Contribution to journalArticle

Paumier, KL, Siderowf, AD, Auinger, P, Oakes, D, Madhavan, L, Espay, AJ, Revilla, FJ & Collier, TJ 2012, 'Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease', Movement Disorders, vol. 27, no. 7, pp. 880-887. https://doi.org/10.1002/mds.24978
Paumier, Katrina L. ; Siderowf, Andrew D. ; Auinger, Peggy ; Oakes, David ; Madhavan, Lalitha ; Espay, Alberto J. ; Revilla, Fredy J. ; Collier, Timothy J. / Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease. In: Movement Disorders. 2012 ; Vol. 27, No. 7. pp. 880-887.
@article{158272bf43d54731b3b5f5680c301f7d,
title = "Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease",
abstract = "This study examined whether antidepressants delay the need for dopaminergic therapy or change the degree of motor impairment and disability in a population of early Parkinson's disease (PD) patients. Preclinical studies have indicated that antidepressants modulate signaling pathways involved in cell survival and plasticity, suggesting they may serve to both treat PD-associated depression and slow disease progression. A patient-level meta-analysis included 2064 patients from the treatment and placebo arms of the following trials: FS1, FS-TOO, ELLDOPA, QE2, TEMPO, and PRECEPT. Depression severity was determined at baseline, and antidepressant use was reported in a medication log each visit. Kaplan-Meier curves and time-dependent Cox proportional hazards models determined associations between depression severity and antidepressant use with the primary outcome, time to initiation of dopaminergic therapy. ANCOVAs determined associations with the secondary outcome, degree of motor impairment and disability, reported as annualized change in UPDRS scores from baseline to final visit. When controlling for baseline depression, the initiation of dopaminergic therapy was delayed for subjects taking tricyclic antidepressants compared with those not taking antidepressants. No significant differences were found in UPDRS scores for subjects taking antidepressants compared with those not taking antidepressants. Tricyclic antidepressants are associated with a delay in reaching the end point of need to start dopaminergic therapy. The lack of change in overall UPDRS scores suggests the delay was not attributable to symptomatic effects.",
keywords = "Antidepressants, Depression, Disease modifying, Parkinson's disease, Retrospective study",
author = "Paumier, {Katrina L.} and Siderowf, {Andrew D.} and Peggy Auinger and David Oakes and Lalitha Madhavan and Espay, {Alberto J.} and Revilla, {Fredy J.} and Collier, {Timothy J.}",
year = "2012",
doi = "10.1002/mds.24978",
language = "English (US)",
volume = "27",
pages = "880--887",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease

AU - Paumier, Katrina L.

AU - Siderowf, Andrew D.

AU - Auinger, Peggy

AU - Oakes, David

AU - Madhavan, Lalitha

AU - Espay, Alberto J.

AU - Revilla, Fredy J.

AU - Collier, Timothy J.

PY - 2012

Y1 - 2012

N2 - This study examined whether antidepressants delay the need for dopaminergic therapy or change the degree of motor impairment and disability in a population of early Parkinson's disease (PD) patients. Preclinical studies have indicated that antidepressants modulate signaling pathways involved in cell survival and plasticity, suggesting they may serve to both treat PD-associated depression and slow disease progression. A patient-level meta-analysis included 2064 patients from the treatment and placebo arms of the following trials: FS1, FS-TOO, ELLDOPA, QE2, TEMPO, and PRECEPT. Depression severity was determined at baseline, and antidepressant use was reported in a medication log each visit. Kaplan-Meier curves and time-dependent Cox proportional hazards models determined associations between depression severity and antidepressant use with the primary outcome, time to initiation of dopaminergic therapy. ANCOVAs determined associations with the secondary outcome, degree of motor impairment and disability, reported as annualized change in UPDRS scores from baseline to final visit. When controlling for baseline depression, the initiation of dopaminergic therapy was delayed for subjects taking tricyclic antidepressants compared with those not taking antidepressants. No significant differences were found in UPDRS scores for subjects taking antidepressants compared with those not taking antidepressants. Tricyclic antidepressants are associated with a delay in reaching the end point of need to start dopaminergic therapy. The lack of change in overall UPDRS scores suggests the delay was not attributable to symptomatic effects.

AB - This study examined whether antidepressants delay the need for dopaminergic therapy or change the degree of motor impairment and disability in a population of early Parkinson's disease (PD) patients. Preclinical studies have indicated that antidepressants modulate signaling pathways involved in cell survival and plasticity, suggesting they may serve to both treat PD-associated depression and slow disease progression. A patient-level meta-analysis included 2064 patients from the treatment and placebo arms of the following trials: FS1, FS-TOO, ELLDOPA, QE2, TEMPO, and PRECEPT. Depression severity was determined at baseline, and antidepressant use was reported in a medication log each visit. Kaplan-Meier curves and time-dependent Cox proportional hazards models determined associations between depression severity and antidepressant use with the primary outcome, time to initiation of dopaminergic therapy. ANCOVAs determined associations with the secondary outcome, degree of motor impairment and disability, reported as annualized change in UPDRS scores from baseline to final visit. When controlling for baseline depression, the initiation of dopaminergic therapy was delayed for subjects taking tricyclic antidepressants compared with those not taking antidepressants. No significant differences were found in UPDRS scores for subjects taking antidepressants compared with those not taking antidepressants. Tricyclic antidepressants are associated with a delay in reaching the end point of need to start dopaminergic therapy. The lack of change in overall UPDRS scores suggests the delay was not attributable to symptomatic effects.

KW - Antidepressants

KW - Depression

KW - Disease modifying

KW - Parkinson's disease

KW - Retrospective study

UR - http://www.scopus.com/inward/record.url?scp=85027927635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027927635&partnerID=8YFLogxK

U2 - 10.1002/mds.24978

DO - 10.1002/mds.24978

M3 - Article

VL - 27

SP - 880

EP - 887

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 7

ER -